Related Experiment Video
Updated: Sep 27, 2025
Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Published on: May 4, 2018
Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections
Robert J Hart1, Lisa A Morici1
1Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, United States.
Abstract:
The bacterium Pseudomonas aeruginosa (Pa) is ubiquitous in the environment and causes opportunistic infections in humans. Pa is increasingly becoming one of the most difficult to treat microorganisms due to its intrinsic and acquired resistance to multiple antibiotics. The World Health Organization estimates that at least 700,000 people die each year from drug resistant microbial infections and have listed Pa as one of three bacterial species for which there is the most critical need for the development of novel therapeutics. Pa is a common cause of bloodstream infections (BSI) and bacterial sepsis. With nearly 49 million sepsis cases and 11 million deaths worldwide, an effective vaccine against Pa could prevent the morbidity and mortality resulting from Pa BSI and lessen our dependence on antibiotics. We reviewed the current landscape of Pa vaccines in pre-clinical and clinical stages over the last two decades. It is readily apparent that Pa vaccine development efforts have been largely directed at the prevention of pulmonary infections, likely due to Pa's devastating impact on individuals with cystic fibrosis. However, the increase in nosocomial infections, BSI-related sepsis, and the emergence of widespread antibiotic resistance have converged as a major threat to global public health. In this perspective, we draw attention to potential Pa vaccine candidates and encourage a renewed effort for prophylactic vaccine development to prevent drug-resistant Pa BSI.
Insights
Pseudomonas aeruginosa (Pa) infections are a growing threat due to antibiotic resistance. Developing a novel vaccine against Pa bloodstream infections (BSI) is crucial to combat sepsis and reduce mortality.
Area of Science:
- Microbiology
- Infectious Diseases
- Vaccinology
Background:
- Pseudomonas aeruginosa (Pa) is an opportunistic pathogen causing difficult-to-treat infections due to rising antibiotic resistance.
- Pa is a leading cause of bloodstream infections (BSI) and sepsis, contributing to significant global morbidity and mortality.
- The World Health Organization identifies Pa as a critical target for novel therapeutic development.
Purpose of the Study:
- To review the landscape of Pa vaccines in pre-clinical and clinical development over the past two decades.
- To highlight the urgent need for prophylactic vaccines targeting Pa bloodstream infections (BSI) and sepsis.
- To encourage renewed efforts in developing vaccines against drug-resistant Pa.
Main Methods:
- Systematic review of pre-clinical and clinical vaccine studies for Pseudomonas aeruginosa over the last 20 years.
- Analysis of vaccine development trends, focusing on targets and infection types.
- Evaluation of the public health impact of Pa BSI and antibiotic resistance.
Main Results:
- Most Pa vaccine development has focused on pulmonary infections, particularly for cystic fibrosis patients.
- There is a critical need for vaccines targeting Pa bloodstream infections (BSI) due to increasing nosocomial infections and sepsis.
- Antibiotic resistance in Pa exacerbates the threat, underscoring the need for alternative prevention strategies.
Conclusions:
- Current vaccine development for Pseudomonas aeruginosa has not adequately addressed the growing threat of BSI and sepsis.
- Prophylactic vaccines against drug-resistant Pa BSI are essential to mitigate global health risks.
- A shift in focus towards BSI prevention is urgently needed in Pa vaccine research and development.
More Related Videos
Related Concept Videos
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
01:26Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...